Related Experiment Video
Updated: Apr 29, 2026

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing
Published on: October 16, 2018
Viral evolutionary changes during tenofovir treatment in a chronic hepatitis B patient with sequential nucleos(t)ide
Hyun Woong Lee1, Hye Young Chang1, Suh Yoon Yang1
1Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
Abstract:
A 54-year-old man diagnosed with HBeAg-positive chronic hepatitis B (CHB) was treated with entecavir (ETV) 1mg/day following an initial unsuccessful lamivudine (LAM) treatment (rtL180M, rtM204V/I). Subsequently, virological breakthrough with ETV mutation (rtT184A/L) developed. The LAM and adefovir combination therapy was followed by virological breakthrough. The therapy had been switched to TDF monotherapy. However, this patient experienced virological breakthrough under TDF with a HBV strain bearing rtL80M, rtL180M, rtM204V/I, rtA200V, rtF221Y, rtS223A, rtT184A/L, rtR153Q, and rtV191I combined mutations without rtA194T mutation. TDF resistance may emerge due to multi-site polymerase mutations rather than single-site polymerase mutation.
Related Concept Videos
Viral Mutations
Retrovirus Life Cycles
Retroviruses
Viral Hepatitis I: Introduction
Subviral Agents
Inhibitors of Viral Protein Synthesis

